Receipt of deferred consideration

About this update from Cambridge Nutritional Sciences Plc

OMEGA DIAGNOSTICS GROUP PLC ("Omega" or the "Company" or the "Group")   Receipt of deferred consideration   Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the £4.0m of deferred consideration relating to the sale of the CD4 business.   Accordingly, as of close of business on 24 November 2022, Omega held cash balances of £6.5m.     The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.     Contacts:   Omega Diagnostics Group PLC www.omegadiagnostics.com Jag Grewal, Chief Executive via Walbrook PR Chris Lea, Chief Financial Officer finnCap Ltd Tel: 020 7220 0500 Geoff Nash/Edward Whiley (Corporate Finance) Alice Lane/ Harriet Ward (ECM) Walbrook PR Limited Tel: 020 7933 8780 or [email protected] Paul McManus / Sam Allen Mob: 07980 541 893 / Mob: 07502 558 258   About Omega Diagnostics Group PLC Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition . www.omegadx.com  

View stock analysis, news, and events for Cambridge Nutritional Sciences Plc